High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

Highlights

1. Escalating Risk with BMI

In patients with stable atherosclerotic cardiovascular disease (ASCVD), every 5-unit increase in Body Mass Index (BMI) above 30 kg/m2 is associated with an 11% higher risk of major adverse cardiovascular events (MACE).

2. Enhanced Relative Efficacy

The relative risk reduction (RRR) for the primary cardiovascular endpoint with evolocumab was progressively greater in patients with higher BMI, reaching 29% in those with a BMI of 35 kg/m2 or higher.

3. Substantial Absolute Benefit

Patients with a BMI of 35 kg/m2 or higher achieved an absolute risk reduction (ARR) of 5.7% over three years, nearly four times higher than the ARR observed in patients with a BMI below 30 kg/m2.

Introduction: The Growing Challenge of Obesity-Associated ASCVD

Obesity has emerged as a global pandemic and a primary driver of atherosclerotic cardiovascular disease (ASCVD). Beyond its association with traditional risk factors such as hypertension and type 2 diabetes, obesity exerts direct pro-inflammatory and pro-thrombotic effects on the vasculature. Despite the widespread use of statins, patients with obesity often harbor significant residual cardiovascular risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab, have demonstrated potent LDL-C lowering and reduction of major adverse cardiovascular events (MACE). However, whether the clinical benefit of these agents varies across the spectrum of body mass index (BMI) has remained a critical question for personalized lipid management. This prespecified analysis of the FOURIER trial provides definitive evidence on how obesity influences both cardiovascular risk and the therapeutic response to evolocumab.

Study Design: A Prespecified Analysis of the FOURIER Trial

The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial was a multinational, randomized, double-blind, placebo-controlled study that enrolled 27,564 patients with stable ASCVD and LDL-C levels of 70 mg/dL or higher while on optimized statin therapy. Participants were randomized to receive either evolocumab (140 mg every 2 weeks or 420 mg monthly) or a matching placebo.

In this prespecified secondary analysis, researchers categorized the population by BMI: <25 kg/m2 (underweight/normal), 25 to <30 kg/m2 (overweight), 30 to <35 kg/m2 (obese), and ≥35 kg/m2 (severely obese). The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The median follow-up period was 2.2 years, with Kaplan-Meier event rates calculated at the 3-year mark. The study utilized Cox proportional hazards models to assess the association between BMI and cardiovascular risk, as well as the interaction between BMI and the efficacy of evolocumab.

Results: BMI as a Potent Predictor of Residual Cardiovascular Risk

Among the 27,564 participants, 40% (n=10,942) had a BMI of 30 kg/m2 or higher, and 13% (n=3,446) had a BMI of 35 kg/m2 or higher. The baseline characteristics indicated that patients in the higher BMI categories were more likely to have comorbid conditions such as hypertension and diabetes, though statin intensity was generally balanced across groups.

The Linear Relationship of Risk

In the placebo arm, BMI was found to be a significant independent predictor of MACE. After adjusting for age, sex, smoking status, and other clinical predictors, every 5-unit increase in BMI above the 30 kg/m2 threshold was associated with an 11% increase in the risk of the primary composite endpoint (adjusted HR: 1.11; 95% CI: 1.02-1.21). This underscores the fact that obesity continues to drive vascular events even in patients receiving contemporary medical therapy.

The Evolocumab Advantage: Enhanced Relative and Absolute Benefits

The most striking finding of the analysis was the significant interaction between BMI and the clinical benefit of evolocumab (P for interaction = 0.025 when modeled on a continuous basis). While evolocumab was effective across all weight categories, the magnitude of the benefit increased sharply as BMI rose.

Relative Risk Reduction (RRR)

In patients with a BMI <30 kg/m2, evolocumab reduced the risk of the primary endpoint by 11% (HR: 0.89; 95% CI: 0.81-0.98). In those with a BMI of 30 to <35 kg/m2, the reduction was 14% (HR: 0.86; 95% CI: 0.75-0.98). Most notably, in patients with severe obesity (BMI ≥35 kg/m2), the risk reduction reached 29% (HR: 0.71; 95% CI: 0.59-0.86). This gradient suggests that the biological pathways targeted by PCSK9 inhibition may be particularly relevant in the setting of obesity-related metabolic dysfunction.

Absolute Risk Reduction (ARR)

The disparity in absolute benefit was even more pronounced. The 3-year ARR for the primary endpoint was 1.4% for those with BMI <30 kg/m2, 1.8% for those with BMI 30 to <35 kg/m2, and a substantial 5.7% for those with BMI ≥35 kg/m2. This translates to a much lower Number Needed to Treat (NNT) for the most obese patients, making evolocumab a highly cost-effective and clinically impactful intervention in this specific subgroup.

Expert Commentary: Mechanistic Insights and Clinical Utility

The observation that evolocumab works better in patients with higher BMI is both clinically relevant and scientifically intriguing. Several mechanisms may explain this phenomenon. Obesity is often associated with higher levels of PCSK9 and a more pro-atherogenic lipid profile, characterized by smaller, denser LDL particles and increased inflammation. By aggressively lowering LDL-C and potentially influencing other pathways, evolocumab may be counteracting the heightened state of vascular vulnerability inherent in obese patients.

Furthermore, this data challenges the so-called “obesity paradox” sometimes seen in cardiovascular literature, where higher BMI is occasionally associated with better outcomes. In the FOURIER population, higher BMI clearly correlated with higher risk, and more importantly, with a higher responsiveness to intensive lipid lowering. This suggests that the metabolic disturbances in obesity provide a “fertile ground” for the protective effects of PCSK9 inhibition.

From a health policy and clinical practice perspective, these results are invaluable. When clinicians face decisions regarding the initiation of expensive therapies like PCSK9 inhibitors, the BMI of the patient should be considered a key factor in the risk-benefit calculus. The 5.7% ARR in patients with BMI ≥35 kg/m2 is among the highest observed in modern lipid trials, suggesting that these patients should be prioritized for treatment.

Study Limitations and Considerations

While the analysis was prespecified, it remains a subgroup analysis. The median follow-up of 2.2 years is relatively short for a chronic condition like obesity-associated ASCVD, and longer-term data would be beneficial. Additionally, BMI is an imperfect measure of adiposity as it does not distinguish between muscle mass and visceral fat. Future studies incorporating waist circumference or imaging-based fat quantification might provide even more granular insights into the relationship between adiposity and PCSK9 inhibition.

Conclusion: A Precision Approach to Lipid Lowering

The FOURIER BMI analysis demonstrates that individuals with obesity and ASCVD face a disproportionately high risk of cardiovascular events, but they also stand to gain the most from PCSK9 inhibition with evolocumab. The dramatic 29% relative risk reduction and 5.7% absolute risk reduction in patients with severe obesity provide a strong mandate for the use of this therapy in this high-risk population. By tailoring lipid-lowering strategies to the patient’s metabolic profile, clinicians can more effectively attenuate the cardiovascular burden of the global obesity epidemic.

References

1. Kang YM, Giugliano RP, Keech AC, et al. Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER. J Am Coll Cardiol. 2025 Dec 10:S0735-1097(25)10005-3. doi: 10.1016/j.jacc.2025.10.036.
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664.
3. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With and Without Diabetes Mellitus: Results From the FOURIER-OLE Study. Circulation. 2022;146(15):1109-1119.